Palatin Announces Positive Topline Results from Phase 2 Ulcerative Colitis (UC) Study of Oral Melanocortin-1 Receptor Agonist PL8177
Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on ...
Clinical Trials Arena on MSN6d
Palatin’s UC therapy prompts clinical remission in a third of patients
A third of patients with active ulcerative colitis (UC) experienced clinical remission in a Phase II trial of Palatin ...
Yahoo Finance10d
Palatin's Oral MC4R Agonist PL7737 Receives FDA Orphan Drug Designation for Obesity Due to Leptin Receptor Deficiency
PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced the US Food & Drug ...
Palatin finishes phase 2 trial in obesity treatment study
The melanocortin 4 receptor (MC4R) pathway, central to the study, is known to play a crucial role in appetite regulation and ...
Palatin says BMT-801 Phase 2 obesity study met primary endpoint
Technologies announced that its BMT-801 Phase 2 obesity co-administration study met its primary endpoint and was highly ...
Medindia3d
Palatin Announces MC4R Agonist Bremelanotide Co-Administered with GLP-1/GIP Tirzepatide Meets Primary Endpoint in Phase 2 Obesity Study
Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, ...
Palatin reports ‘positive’ results from Phase 2 study of PL8177
Technologies announced positive topline results from its Phase 2 study of PL8177, a selective melanocortin-1 receptor agonist, in ...
Queen Mary University of London4y
Professor Li Chan
She first joined the Centre for Endocrinology in 2005 to undertake her PhD investigating a novel receptor trafficking protein MRAP2 (melanocortin receptor accessory protein two). This was funded by a ...
Morningstar7d
Palatin Announces Positive Topline Results from Phase 2 Ulcerative Colitis (UC) Study of Oral Melanocortin-1 Receptor Agonist PL8177
Orally administered PL8177 is designed to target melanocortin-1 receptors on the surface of cells lining the colon. In a Phase 1 clinical trial, the oral version of PL8177 was shown to effectively ...
Palatin's Oral MC4R Agonist PL7737 Receives FDA Orphan Drug Designation for Obesity Due to Leptin Receptor Deficiency
Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on ...
Palatin Technologies, Inc.: Palatin's Oral MC4R Agonist PL7737 Receives FDA Orphan Drug Designation for Obesity Due to Leptin Receptor Deficiency
Initiated IND-enabling toxicology program IND submission planned for 4Q25; Clinical data expected in 1H26 CRANBURY, N.J., March 25, 2025 /PRNewswire/ -- Palatin ...